Literature DB >> 20674593

The role of the core imaging laboratory in multicenter trials.

John Seibyl1, Kenneth Marek, I George Zubal.   

Abstract

The incorporation of imaging biomarkers and clinical trials is now common. Because of the multiple technical, clinical, and regulatory demands to ensure high-quality quantitative information, the core laboratory serves as a critical intermediary between the study sponsor and the site. It provides unique expertise not found in typical clinical research organizations. This expertise goes far beyond the passive receipt of images for conductance of central reads of data and includes the proactive and early involvement in the selection of sites for imaging, the qualification and assistance for managing the local site logistics, on-the-fly and active quality control of imaging data in close working relationship with sites, and preparation for and conductance of central image reads or quantification in a manner which bears up to regulatory scrutiny. Copyright 2010 Elsevier Inc. All rights reserved.

Mesh:

Year:  2010        PMID: 20674593     DOI: 10.1053/j.semnuclmed.2010.03.002

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  3 in total

Review 1.  The Parkinson Progression Marker Initiative (PPMI).

Authors: 
Journal:  Prog Neurobiol       Date:  2011-09-14       Impact factor: 10.885

2.  Multisite, multimodal neuroimaging of chronic urological pelvic pain: Methodology of the MAPP Research Network.

Authors:  Jeffry R Alger; Benjamin M Ellingson; Cody Ashe-McNalley; Davis C Woodworth; Jennifer S Labus; Melissa Farmer; Lejian Huang; A Vania Apkarian; Kevin A Johnson; Sean C Mackey; Timothy J Ness; Georg Deutsch; Richard E Harris; Daniel J Clauw; Gary H Glover; Todd B Parrish; Jan den Hollander; John W Kusek; Chris Mullins; Emeran A Mayer
Journal:  Neuroimage Clin       Date:  2016-01-06       Impact factor: 4.881

3.  The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Authors:  Diane Stephenson; Derek Hill; Jesse M Cedarbaum; Maria Tome; Spiros Vamvakas; Klaus Romero; Daniela J Conrado; David T Dexter; John Seibyl; Danna Jennings; Timothy Nicholas; Dawn Matthews; Zhiyong Xie; Syed Imam; Paul Maguire; David Russell; Mark Forrest Gordon; Glenn T Stebbins; Ed Somer; Jill Gallagher; Arthur Roach; Peter Basseches; Donald Grosset; Kenneth Marek
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.